GeneHealth - Your precision medicine

Restless Legs Syndrome

Disease Details

Family Health Simplified

Buy Membership

Description: Restless legs syndrome (RLS) is a neurological disorder characterized by an uncontrollable urge to move one's legs, usually due to uncomfortable sensations.
Type: Restless Legs Syndrome (RLS) is a neurological disorder. The type of genetic transmission can vary, but it is often inherited in an autosomal dominant pattern. This means that having just one copy of the mutated gene from either parent can increase the likelihood of developing the condition. However, multiple genetic and environmental factors may contribute to its occurrence.
Signs And Symptoms: RLS sensations range from pain or an aching in the muscles, to "an itch you can't scratch", a "buzzing sensation", an unpleasant "tickle that won't stop", a "crawling" feeling, or limbs jerking while awake. The sensations typically begin or intensify during quiet wakefulness, such as when relaxing, reading, studying, or trying to sleep.It is a "spectrum disorder" with some people experiencing only a minor annoyance and others having major disruption of sleep and impairments in quality of life.The sensations—and the need to move—may return immediately after ceasing movement or at a later time. RLS may start at any age, including childhood, and is a progressive disease for some, while the symptoms may remit in others. In a survey among members of the Restless Legs Syndrome Foundation, it was found that up to 45% of patients had their first symptoms before the age of 20 years.
"An urge to move, usually due to uncomfortable sensations that occur primarily in the legs, but occasionally in the arms or elsewhere." The sensations are unusual and unlike other common sensations. Those with RLS have a hard time describing them, using words or phrases such as uncomfortable, painful, 'antsy', electrical, creeping, itching, pins and needles, pulling, crawling, buzzing, and numbness. It is sometimes described similar to a limb 'falling asleep' or an exaggerated sense of positional awareness of the affected area. The sensation and the urge can occur in any body part; the most cited location is legs, followed by arms. Some people have little or no sensation, yet still, have a strong urge to move.
"Motor restlessness, expressed as activity, which relieves the urge to move." Movement usually brings immediate relief, although temporary and partial. Walking is most common; however, stretching, yoga, biking, or other physical activity may relieve the symptoms. Continuous, fast up-and-down movements of the leg, and/or rapidly moving the legs toward then away from each other, may keep sensations at bay without having to walk. Specific movements may be unique to each person.
"Worsening of symptoms by relaxation." Sitting or lying down (reading, plane ride, watching TV) can trigger the sensations and urge to move. Severity depends on the severity of the person's RLS, the degree of restfulness, duration of the inactivity, etc.
"Variability over the course of the day-night cycle, with symptoms worse in the evening and early in the night." Some experience RLS only at bedtime, while others experience it throughout the day and night. Most people experience the worst symptoms in the evening and the least in the morning.
"Restless legs feel similar to the urge to yawn, situated in the legs or arms." These symptoms of RLS can make sleeping difficult for many patients and a 2005 National Sleep Foundation poll shows the presence of significant daytime difficulties resulting from this condition. These problems range from being late for work to missing work or events because of drowsiness. Patients with RLS who responded reported driving while drowsy more than patients without RLS. These daytime difficulties can translate into safety, social and economic issues for the patient and for society.RLS may contribute to higher rates of depression and anxiety disorders in RLS patients.
Prognosis: RLS symptoms may gradually worsen with age, although more slowly for those with the idiopathic form of RLS than for people who also have an associated medical condition. Current therapies can control the disorder, minimizing symptoms and increasing periods of restful sleep. In addition, some people have remissions, periods in which symptoms decrease or disappear for days, weeks, or months, although symptoms usually eventually reappear. Being diagnosed with RLS does not indicate or foreshadow another neurological disease, such as Parkinson's disease. RLS symptoms can worsen over time when dopamine-related drugs are used for therapy, an effect called augmentation which may represent symptoms occurring throughout the day and affect movements of all limbs. There is no cure for RLS.
Onset: The onset of Restless Legs Syndrome (RLS) can occur at any age, including childhood, but it most commonly begins during middle age or later. Symptoms often worsen with age.
Prevalence: Restless Legs Syndrome (RLS) affects approximately 5-10% of the population in the United States and Europe. It is more common in women than in men, and its prevalence tends to increase with age.
Epidemiology: RLS affects an estimated 2.5–15% of the American population. A minority (around 2.7% of the population) experience daily or severe symptoms. RLS is twice as common in women as in men, and Caucasians are more prone to RLS than people of African descent. RLS occurs in 3% of individuals from the Mediterranean or Middle Eastern regions, and in 1–5% of those from East Asia, indicating that different genetic or environmental factors, including diet, may play a role in the prevalence of this syndrome. RLS diagnosed at an older age runs a more severe course. RLS is even more common in individuals with iron deficiency, pregnancy, or end-stage kidney disease. The National Sleep Foundation's 1998 Sleep in America poll showed that up to 25 percent of pregnant women developed RLS during the third trimester. Poor general health is also linked.There are several risk factors for RLS, including old age, family history, and uremia. The prevalence of RLS tends to increase with age, as well as its severity and longer duration of symptoms. People with uremia receiving renal dialysis have a prevalence from 20% to 57%, while those having kidney transplant improve compared to those treated with dialysis.RLS can occur at all ages, although it typically begins in the third or fourth decade.
Genome‐wide association studies have now identified 19 risk loci associated with RLS. Neurological conditions linked to RLS include Parkinson's disease, spinal cerebellar atrophy, spinal stenosis, lumbosacral radiculopathy and Charcot–Marie–Tooth disease type 2.
Intractability: Restless Legs Syndrome (RLS) is generally not considered intractable. Many patients experience significant relief from symptoms with appropriate treatment, which may include lifestyle changes, medications, and addressing underlying conditions such as iron deficiency. However, RLS can be chronic and may require ongoing management.
Disease Severity: Restless Legs Syndrome (RLS) can vary in severity among individuals. Some may experience mild symptoms that are manageable and infrequent, while others may have more severe symptoms that lead to significant discomfort and interfere with daily activities, particularly sleep. The severity can often be categorized into mild, moderate, severe, and very severe based on the frequency and intensity of symptoms, as well as the degree to which they affect quality of life.
Healthcare Professionals: Disease Ontology ID - DOID:0050425
Pathophysiology: Pathophysiology: Restless Legs Syndrome (RLS) is a neurological disorder characterized by an uncontrollable urge to move the legs, typically accompanied by uncomfortable sensations. The exact pathophysiology is not fully understood, but it's believed to involve dysregulation in dopaminergic pathways in the brain, particularly in the basal ganglia. Iron deficiency in the brain is also thought to play a crucial role, as iron is a cofactor in dopamine synthesis. Genetic factors and abnormalities in certain genes have been implicated in familial cases. Additionally, conditions such as peripheral neuropathy, kidney failure, and pregnancy can exacerbate or trigger RLS symptoms.
Carrier Status: Restless legs syndrome (RLS) does not have a defined carrier status, as it is not a condition typically associated with simple genetic inheritance patterns. The condition can be influenced by multiple genetic and environmental factors.
Mechanism: Although it is only partly understood, pathophysiology of restless legs syndrome may involve dopamine and iron system anomalies. There is also a commonly acknowledged circadian rhythm explanatory mechanism associated with it, clinically shown simply by biomarkers of circadian rhythm, such as body temperature. The interactions between impaired neuronal iron uptake and the functions of the neuromelanin-containing and dopamine-producing cells have roles in RLS development, indicating that iron deficiency might affect the brain dopaminergic transmissions in different ways.Medial thalamic nuclei may also have a role in RLS as part as the limbic system modulated by the dopaminergic system which may affect pain perception. Improvement of RLS symptoms occurs in people receiving low-dose dopamine agonists.
Treatment: If RLS is not linked to an underlying cause, its frequency may be reduced by lifestyle modifications such as adopting improving sleep hygiene, regular exercise, and stopping smoking. Medications used may include dopamine agonists and gabapentinoids in those with daily restless legs syndrome. In severe or refractory cases, opioids have been used.Treatment of RLS should not be considered until possible medical causes are ruled out. Secondary RLS may be cured if precipitating medical conditions (anemia) are managed effectively.
Compassionate Use Treatment: Restless Legs Syndrome (RLS) often frustrates patients due to limited treatment options. Among compassionate use and off-label treatments, several options have shown promise:

1. **Intravenous Iron Therapy**: While oral iron supplements are commonly used, intravenous iron has been explored for patients with severe RLS unresponsive to other treatments.

2. **Dopamine Agonists**: Although medications like ropinirole and pramipexole are approved for RLS, higher or adjusted doses might be used off-label in certain cases.

3. **Anticonvulsants**: Gabapentin enacarbil is approved, but other formulations of gabapentin or pregabalin might be used off-label for managing symptoms.

4. **Opiates**: In severe cases unresponsive to other treatments, opioids like oxycodone are sometimes used off-label under careful medical supervision due to their potential for dependency.

5. **Clonidine**: Occasionally used off-label in patients with resistant RLS due to its sympatholytic effects.

6. **Medical Cannabis**: Some studies suggest benefit for RLS, though it's not widely accepted and often considered experimental.

These treatments are tailored on a case-by-case basis, typically under the supervision of a healthcare provider familiar with RLS.
Lifestyle Recommendations: Lifestyle recommendations for managing Restless Legs Syndrome (RLS) include:

1. **Regular Exercise**: Engage in moderate physical activity regularly, but avoid intense exercise close to bedtime.
2. **Sleep Hygiene**: Maintain a regular sleep schedule and create a comfortable sleep environment.
3. **Avoid Caffeine and Alcohol**: Reduce or eliminate the intake of caffeine and alcohol, especially in the evening.
4. **Stay Hydrated**: Ensure adequate fluid intake throughout the day.
5. **Warm Baths and Massages**: Taking a warm bath or having a leg massage before bedtime can help relax muscles.
6. **Comfortable Leg Positioning**: Keep your legs uncrossed and use pillows for support while sitting or lying down.
7. **Stress Management**: Practice relaxation techniques such as deep breathing, meditation, or yoga to reduce stress.
8. **Diet**: Maintain a balanced diet rich in iron, folate, and magnesium. Consult a healthcare provider if supplements are needed.

Implementing these lifestyle changes may help alleviate the symptoms of RLS.
Medication: For those whose RLS disrupts or prevents sleep or regular daily activities, medication may be useful. Evidence supports the use of dopamine agonists including pramipexole, ropinirole, rotigotine, cabergoline, and pergolide. They reduce symptoms, improve sleep quality and quality of life. Levodopa is also effective. However, pergolide and cabergoline are less recommended due to their association with increased risk of valvular heart disease. Ropinirole has a faster onset with shorter duration. Rotigotine is commonly used as a transdermal patch which continuously provides stable plasma drug concentrations, resulting in its particular therapeutic effect on patients with symptoms throughout the day. A 2008 meta-analysis found pramipexole to be better than ropinirole.There are, however, issues with the use of dopamine agonists including augmentation. This is a medical condition where the drug itself causes symptoms to increase in severity and/or occur earlier in the day. Dopamine agonists may also cause rebound when symptoms increase as the drug wears off. In many cases, the longer dopamine agonists have been used, the higher the risk of augmentation and rebound as well as the severity of the symptoms. Patients may also develop dopamine dysregulation syndrome, meaning that they can experience an addictive pattern of dopamine replacement therapy. A 2007 study indicated that dopamine agonists used in restless legs syndrome can lead to an increase in compulsive gambling. Patients may also exhibit other impulse-control disorders such as compulsive shopping and compulsive eating. There are some indications that stopping the dopamine agonist treatment has an impact on the resolution or at least improvement of the impulse-control disorder, even though some people can be particularly exposed to dopamine agonist withdrawal syndrome.Gabapentinoids (α2δ ligands), including gabapentin, pregabalin, and gabapentin enacarbil, are also widely used in the treatment of RLS. They are used as first-line treatments similarly to dopamine agonists, and as of 2019, guidelines have started to recommend gabapentinoids over dopamine agonists as initial therapy for RLS due to higher known risks of symptom augmentation with long-term dopamine agonist therapy. Gabapentin enacarbil is approved by regulatory authorities for the treatment of RLS, whereas gabapentin and pregabalin are used off-label. Data on gabapentinoids in the treatment of RLS are more limited compared to dopamine agonists. However, based on available evidence, gabapentinoids are similarly effective to dopamine agonists in the treatment of RLS.Low doses of opioids are used in the treatment of severe and treatment-resistant cases and are recommended by multiple reputable medical guidelines. The most commonly used agents are prolonged-release oxycodone and methadone, but other opioids, including tramadol, codeine, morphine, and hydrocodone, may also be considered. Opioids are only indicated in severe cases that do not respond to other measures due to their very high abuse liability and high rate of side effects, which may include constipation, fatigue, and headache. However, opioids are said to be highly effective for severe and refractory RLS, and can be helpful in well-selected individuals.Benzodiazepines, such as diazepam or clonazepam, are not generally recommended, and their effectiveness is unknown or contradictory. They, however, are sometimes still used as a second-line treatment, as add-on agents. Other treatments have also been explored, such as valproate, carbamazepine, perampanel, and dipyridamole, but are either not effective or have insufficient data to support their use.
Repurposable Drugs: Repurposable drugs for Restless Legs Syndrome (RLS) include:

1. **Gabapentin**: Originally an anticonvulsant, it is often used to treat nerve pain and has shown effectiveness in RLS.
2. **Pramipexole**: A dopamine agonist primarily used for Parkinson's disease, it is also effective in managing RLS symptoms.
3. **Ropinirole**: Another dopamine agonist intended for Parkinson's disease, similarly effective for RLS.
4. **Clonazepam**: A benzodiazepine used for seizures and anxiety that may relieve RLS symptoms, although dependency risks exist.
5. **Pregabalin**: Like gabapentin, it’s used for neuropathic pain and seizures, and can be effective for RLS.

Always consult a healthcare professional before starting any treatment.
Metabolites: For restless legs syndrome (RLS), the primary metabolic factors of interest include iron metabolism and dopamine function. Low levels of iron in the brain and altered dopamine activity are commonly implicated in the pathophysiology of RLS. Metabolites such as ferritin (an iron storage protein) may be assessed, as lower ferritin levels can be associated with RLS. Dopamine's precursor, L-DOPA, and other related metabolites might also be relevant in understanding the disorder.

No additional detailed metabolites named "nan" are specifically linked or recognized in relation to RLS.
Nutraceuticals: Restless Legs Syndrome (RLS) is characterized by an uncontrollable urge to move the legs, typically in the evenings. Nutraceuticals that may help manage RLS symptoms include:

1. **Iron Supplements**: Low iron levels are often implicated in RLS. Correcting iron deficiency through supplementation can alleviate symptoms.
2. **Magnesium**: Magnesium can help relax muscles and improve sleep quality, potentially reducing RLS symptoms.
3. **Folate (Vitamin B9)**: Folate deficiency has been associated with RLS. Supplementing with folate may help in managing the condition.
4. **Vitamin D**: Adequate levels of vitamin D may help reduce symptoms, as low levels have been observed in some RLS patients.
5. **Vitamin C and E**: Antioxidant properties of these vitamins may help in managing symptoms, especially in patients undergoing dialysis.
6. **Omega-3 Fatty Acids**: These can support brain health and may alleviate RLS symptoms in some individuals.

It’s essential to consult a healthcare provider before starting any supplements to ensure they are safe and appropriate for your specific condition.
Peptides: Restless Legs Syndrome (RLS) is a neurological disorder that causes an irresistible urge to move the legs, often accompanied by uncomfortable sensations. The role of peptides in RLS is not fully established, but certain neuropeptides may be involved in its pathophysiology. For instance, orexin (also known as hypocretin) and endorphins have been studied for their potential effects on sleep and pain modulation, which are relevant to RLS symptoms. Additionally, some research implicates dysfunction in the dopaminergic system, where peptides might also play a modulatory role.

NAN (nanoparticles) have been explored in various medical fields for targeted drug delivery, including neurological disorders. For RLS, although direct application of nanoparticles is still largely experimental, nanotechnology could potentially improve the delivery and efficacy of treatments, such as those targeting dopamine receptors or other molecular pathways involved in RLS.